Flushing and gastrointestinal tolerability events in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 dimethyl fumarate) in the phase 3 DEFINE and CONFIRM trials

被引：0
|
作者：
Selmaj, K. [1 ]
Gold, R. [2 ]
Fox, R. J. [3 ]
Havrdova, E. [4 ]
Giovannoni, G. [5 ]
Pace, A.
Novas, M.
Meltzer, L.
Hotermans, C.
Viglietta, V.
Phillips, J. T. [6 ]
机构：
[1] Med Univ Lodz, Lodz, Poland
[2] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[3] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[4] Charles Univ Prague, Prague, Czech Republic
[5] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[6] Baylor Inst Immunol Res, Dallas, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：221 / 221
页数：1
相关论文
共 50 条
  • [21] Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis
    Selmaj, K.
    Gold, R.
    Kappos, L.
    Bar-Or, A.
    Arnold, D.
    Giovannoni, G.
    Sweetser, M.
    Novas, M.
    Raghupathi, K.
    Dawson, K.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S451 - S451
  • [22] Safety and Tolerability of Oral BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): Interim Results from ENDORSE Extension Study
    Phillips, J. Theodore
    Fox, Robert
    Selmaj, Krzysztof
    Raghupathi, Kartik
    Yuan, Huixing
    Novas, Mark
    Sweetser, Marianne
    Viglietta, Vissia
    Dawson, Katherine
    Gold, Ralf
    NEUROLOGY, 2013, 80
  • [23] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
    Michael Hutchinson
    Robert J. Fox
    David H. Miller
    J. Theodore Phillips
    Mariko Kita
    Eva Havrdova
    John O’Gorman
    Ray Zhang
    Mark Novas
    Vissia Viglietta
    Katherine T. Dawson
    Journal of Neurology, 2013, 260 : 2286 - 2296
  • [24] Clinical efficacy of BG-12 (dimethyl fumarate) for relapsing remitting multiple sclerosis according to prior therapy: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Hutchinson, M.
    Gold, R.
    Fox, R. J.
    Havrdova, E.
    Giovannoni, G.
    Zhang, A.
    Hotermans, C.
    Stephan, M.
    Bar-Or, A.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 235 - 235
  • [25] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study
    Amit Bar-Or
    Ralf Gold
    Ludwig Kappos
    Douglas L. Arnold
    Gavin Giovannoni
    Krzysztof Selmaj
    John O’Gorman
    Monica Stephan
    Katherine T. Dawson
    Journal of Neurology, 2013, 260 : 2297 - 2305
  • [26] Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study
    Kappos, Ludwig
    Gold, Ralf
    Arnold, Douglas L.
    Bar-Or, Amit
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Sarda, Sujata P.
    Agarwal, Sonalee
    Zhang, Annie
    Sheikh, Sarah I.
    Seidman, Emily
    Dawson, Katherine T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (02) : 243 - 252
  • [27] 3-Year Follow-up of Oral BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated MRI Outcomes from the DEFINE, CONFIRM, and ENDORSE studies
    Miller, D. H.
    Fox, R. J.
    Gold, R.
    Havrdova, E.
    Kappos, L.
    Yousry, T.
    Rana, J.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Sheikh, S. I.
    Dawson, K. T.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 932 - 932
  • [28] An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Miller, D. H.
    Arnold, D. L.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    Hutchinson, M.
    JOURNAL OF NEUROLOGY, 2013, 260 : S13 - S13
  • [29] Advances in the management of relapsing-remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)
    Nielsen, A. Scott
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2015, 5
  • [30] Lymphocyte count reductions in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 (dimethyl fumarate): integrated analysis of the placebo-controlled studies
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Selmaj, K.
    Raghupathi, K.
    Yuan, H.
    O'Gorman, J.
    Novas, M.
    Viglietta, V.
    Kurukulasuriya, N. C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 469 - 469
12345